SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors engage in high-risk, speculative activity characterized by intense volatility and rapid price swings common in meme coin cycles. The community is actively debating the project's long-term sustainability while others discuss potential entry points and strategies for navigating what many characterize as a high-stakes pump and dump cycle.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The DIA is currently caught in intense volatility as traders debate the legitimacy of contradictory reports regarding U.S.-Iran negotiations, with community sentiment deeply polarized between optimism for a de-escalation deal and skepticism over perceived market manipulation. Investors remain highly sensitive to geopolitical headlines, as the community actively discusses the risk of a potential ground invasion versus a short-term relief rally.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy is capturing significant attention following its recent Nasdaq listing, driven by high-stakes speculation surrounding its exploration rights for a vast oil basin in the Jameson Land region. While the community is actively debating the company's long-term potential and the credibility of its leadership, many traders are closely monitoring price volatility and volume as they weigh the speculative nature of these Arctic drilling plans.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is trending following its recent Nasdaq debut via a SPAC merger, sparking intense community debate regarding stock availability, alleged broker settlement delays, and concerns over potential market manipulation. Investors are actively discussing the firm's photonic quantum computing prospects alongside technical speculation about float dynamics and potential short-term volatility.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is currently a focal point for crypto traders as the community debates its long-term potential against a backdrop of technical volatility and upcoming regulatory developments like the Clarity Act. While some investors are accumulating aggressively, citing supply dynamics and potential institutional interest as catalysts for a breakout, others remain skeptical, pointing to the asset's recent underperformance and lack of ETF inflows.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is capturing significant trader attention as part of a speculative rotation into aquatic-themed meme coins following recent movements in similar tokens. The community is actively debating the potential for quick gains, with proponents pushing the narrative of low market capitalization while skeptics warn of volatility and typical meme coin risks.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently generating significant controversy as investors debate whether it is a legitimate Layer-1 blockchain project or a sophisticated scam, with many citing frustration over delayed token claims, locked wallets, and confusing market data. While some community members remain optimistic about long-term potential and mining rewards, others are actively warning of a "rug pull" due to widespread technical issues and concerns over the authenticity of its trading venues.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is experiencing heightened volatility and intense social media discourse as investors debate its long-term potential against a backdrop of macroeconomic uncertainty and sector-wide sentiment shifts. The community remains sharply divided, with bulls aggressively citing strong earnings momentum and data-moat advantages as a reason to buy the dip, while bears express concern over macro pressures and the stock's tendency to trade as a high-beta asset.

Investment Managers Series Trust II - Alternative Access First Priority CLO Bond ETF

Listed Funds Trust - AAF First Priority CLO Bond ETF

Investors are actively discussing $AAA as a potential cash alternative, with many participants highlighting its performance during ex-dividend dates. The conversation frequently features technical testing and broader market commentary as users evaluate the fund's role within their portfolios.

The Shrimp Army

SHRIMPS is trending as part of a broader wave of speculative ocean-themed meme coins that the community is actively trading for quick momentum gains. Participants are intensely focused on rapid volatility and the potential for these micro-cap tokens to drop zeros, though many caution others about the high risk of rug pulls and the necessity of taking profits early.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials

Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials PR...

<ul class="summary-bullets"><li>OSR Holdings has until Aug. 31, 2026, to maintain a closing share price of at least $1 for ten consecutive business days.</li><li>Unit Vaximm immuno-oncology asset is pursuing a global licensing deal immuno-oncology asset that could include a $30 million upfront payment and $815 million in milestones.</li><li>OSR said that it is progressing with the planned merger of its units, RMC and Woori IO.</li></ul>Shares of OSR Holdings, Inc. (OSRH) surged more than 20% on Thursday after the company announced that it received an additional 180-day extension from Nasdaq to regain compliance with the exchange’s minimum bid price requirement.On a closing basis, <a href="https://stocktwits.com/symbol/OSRH">OSRH stock</a> is on track to record its biggest intra-day gains so far this year.Nasdaq initially notified OSR Holdings on Sept. 9, 2025, that it was not in compliance with the exchange’s $1 minimum bid price rule after its shares had traded below that level from August 25. OSR was given till March 4, 2026, to regain compliance.The company now has until Aug. 31, 2026, to meet the rule by maintaining a closing share price of at least $1 for ten consecutive business days. OSR noted that there is no immediate impact on the listing or trading of its stock.“We view this extension as a clear operational runway for our strategic initiatives to mature and translate into tangible shareholder value. With multiple near-term catalysts advancing, we believe OSR Holdings is well positioned to strengthen its capital markets profile and return to compliance through disciplined execution,” said Tim Smith, Head of Investor Relations.<h2 class="st-heading-2">Vaximm’s Potential Global Licensing Deal Could Fetch $815 Million</h2>Meanwhile, the company said it remains focused on several strategic initiatives. Its unit Vaximm is working toward a potential global licensing deal for its immuno-oncology asset VXM01, which could include $30 million upfront and up to $815 million in milestone payments.OSR is also progressing with the planned merger of its units, RMC and Woori IO, to build an integrated medical technology and distribution platform, while exploring global partnerships for Woori IO’s non-invasive glucose monitoring technology.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high message volumes.One user expects the stock to reach $10 in the short term.<stembedurl>https://stocktwits.com/JJBurch/message/646695066</stembedurl>The stock has shed around 15% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did OSRH Stock Jump 20% Today?

The company received an additional 180-day extension from Nasdaq to regain compliance after receiving an initial notice on Sept. 9, 2025.

Equity

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical...

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to...

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones Vaximm, an OSR Company, Receives Binding Term...

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR...

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank">NASDAQ: OSRH</a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

OSR Holdings Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

OSRH
OSR Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OSRH News

OSRHOSR Holdings Inc